Retroscreen is a virology healthcare business which provides clinical and pre-clinical analytical services for flu and cold antiviral products to global pharmaceutical and biotechnology organisations. As the business develops, it intends to expand into adjacent clinical areas, such as asthma.
Kym Denny, CEO of Retroscreen, said: "I am delighted that Retroscreen has today joined AIM and I would like to welcome all our new shareholders to the Company. It is a very exciting day for Retroscreen, and one which we believe will be transformational for the development of the business.”
The Pinsent Masons team advising on the deal was led by Corporate Partner Russell Booker, assisted by Corporate Senior Associate Iain Butler, Corporate Solicitor James Paton-Philip, Legal Director Louise Fullwood (Commercial), Employment Partner Michael Ryley and Tax Senior Associate Conor Brindley.
Commenting on the deal, Russell said: "We are delighted to have assisted Retroscreen with the AIM listing, which will enable the business to expand its clinical and pre-clinical offering in the UK."